Industry

– Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome – Maralixibat data highlighting predictors of event-free survival in patients with Alagille syndrome nominated for prestigious Alex Mowat Prize – New analysis further characterizes 4-year growth improvement in Alagille syndrome, as well as reports on real world experience … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to … [Read more…]

The positive opinion is based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the efficacy and safety of ibrutinib plus venetoclax in patients with previously untreated CLL1,2 If approved, this will be the first all-oral, once daily, fixed-duration, combination regimen for first-line treatment of CLL BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies … [Read more…]

CF602’s unique mechanism of action enables potential treatment of diabetic patients and may offer an alternative to PDE5 (Viagra, Cialis, Levitra, and Stendra) non-responders accounting for 30-35% of the $3.6 billion ED market Patents granted in numerous healthcare markets including the U.S., Australia, and Japan PETACH TIKVA, Israel–(BUSINESS WIRE)–$CANF—Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: … [Read more…]

Flow sponsorship with Pride Toronto promotes both sustainable and healthy choices for consumers TORONTO–(BUSINESS WIRE)–Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) (“Flow” or the “Company”) today announced its official sponsorship of Pride Toronto, participating in various events throughout June to help inspire people to make more sustainable and healthy choices for themselves and the planet. Flow will … [Read more…]

BURLINGTON, N.C. & ALDIE, Va.–(BUSINESS WIRE)–Labcorp, a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions. Labcorp has signed Tigerlily’s #InclusionPledge for Black Women, joining other healthcare and life … [Read more…]

Approval based on recurrence-free survival and distant metastasis-free survival benefit demonstrated by KEYTRUDA in the Phase 3 KEYNOTE-716 trial KEYTRUDA is the first anti-PD-1 immunotherapy approved in the EU for patients 12 years and older as adjuvant treatment across stage IIB, IIC and III melanoma following complete resection and for the treatment of advanced (unresectable … [Read more…]

FRISCO, Texas–(BUSINESS WIRE)–Magellan Healthcare, the behavioral and specialty healthcare segment of Magellan Health, Inc., today announced resources and programs in support of Black, Indigenous and People of Color (BIPOC) Mental Health Awareness Month in July. One in five Americans has been diagnosed with a mental health or substance use condition.1 While BIPOC experience relatively similar … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Oscillating Positive Expiratory Pressure Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product, Indication, and Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The oscillating positive expiratory pressure (OPEP) devices market is expected to grow from US$ 125.66 million in 2021 to US$ 179.34 million by 2028; … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Peripheral T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of … [Read more…]